Abstract
Tamoxifen (TAM) is used as the standard endocrine therapy for breast cancer patients and as a chemopreventive agent for women at high risk for this disease. Unfortunately, treatment of TAM increases the incidence of endometrial cancer; this may be due to the genotoxic damage induced by TAM metabolites. Formation of TAM-DNA adducts in rat liver correlates with the development of hepatocarcinoma. TAM-DNA adducts are proposed to be formed through O-sulfonation and/or O-acetylation of α-hydroxylated TAM and its metabolites. However, the role of O-sulfonation and O-acetylation in the formation of TAM-DNA adducts has not been extensively investigated. Rat or human hydroxysteroid sulfotransferases (HST), acetyltransferases, and liver cytosol were incubated with calf thymus DNA, α-OHTAM, and either 3′-phosphoadenosine 5′-phosphosulfate (PAPS) or acetyl coenzyme A (acetyl-CoA) as a cofactor and analyzed for TAM-DNA adduct formation, using 32P postlableling/polyacrylamide gel electrophoresis analysis. TAM-DNA adduct was formed when PAPS, not acetyl-CoA, was used. No TAM-DNA adducts were produced using human N-acetyltransferase I and II. HST antibody inhibited approximately 90% of TAM-DNA adduct formation generated by the cytosol or HST, suggesting that HST is primarily involved in the formation of TAM-DNA adducts. The formation of TAM-DNA adducts with rat liver cytosol and HST was much higher than that of human liver cytosol and HST. Our results indicate that TAM-DNA adducts are formed via O-sulfonation, not O-acetylation, of α-hydroxylated TAM and its metabolites.
Footnotes
-
This research was supported by Grants ES09418 (to S.S.) from the National Institute of Environmental Health Sciences and CA38683 (to M.W.D.) from the National Cancer Institute.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.105.005330.
-
ABBREVIATIONS: TAM, tamoxifen; α-OHTAM, α-hydroxytamoxifen; fr, fraction(s); dG-N2-TAM, α-(N2-deoxyguanosinyl)tamoxifen; α-OH-N-desTAM, α-hydroxy-N-desmethyltamoxifen; α-OHTAM N-oxide, α-hydroxytamoxifen N-oxide; dG-N2-N-desTAM, α-(N2-deoxyguanosinyl)-N-desmethyltamoxifen; HST, hydroxysteroid sulfotransferase(s); dG3′p-N2-TAM, dG3′p-monophosphate-N2-tamoxifen; PAPS, 3′-phosphoadenosine 5′-phosphosulfate; acetyl-CoA, acetyl coenzyme A; NAT, N-acetyltransferase; DHEA, dehydroepiandrosterone; PAGE, polyacrylamide gel electrophoresis; HPLC, high-performance liquid chromatography.
- Received April 26, 2005.
- Accepted August 11, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|